Targeting KIR blockade in multiple myeloma: Trouble in checkpoint paradise?

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Findings within the current issue indicate that treatment with IPH2101 when used as a monotherapy in smoldering multiple myeloma, meant to enhance natural killer (NK) cell function through inhibitory KIR blockade, results in a surprising reduction of NK-cell function mediated through monocyte trogocytosis. The significance of these findings is discussed.

Original languageEnglish (US)
Pages (from-to)5161-5163
Number of pages3
JournalClinical Cancer Research
Issue number21
StatePublished - Nov 1 2016

Bibliographical note

Funding Information:
J.S. Miller has ownership interests (including patents) at Fate Therapeutics and Oxis Biotech, is a consultant/advisory board member for Celgene, Fate Therapeutics, and Oxis Biotech, reports receiving commercial research grants from Fate Therapeutics and Oxis Biotech, and reports receiving commercial research support from Celgene. No potential conflicts of interest were disclosed by the other author.

Publisher Copyright:
©2016 AACR.


Dive into the research topics of 'Targeting KIR blockade in multiple myeloma: Trouble in checkpoint paradise?'. Together they form a unique fingerprint.

Cite this